company background image
GNFT logo

Genfit ENXTPA:GNFT Stock Report

Last Price

€3.32

Market Cap

€165.0m

7D

2.3%

1Y

-8.3%

Updated

27 Mar, 2024

Data

Company Financials +

GNFT Stock Overview

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases.

GNFT fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Rewards

Risk Analysis

No risks detected for GNFT from our risk checks.

Genfit S.A. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Genfit
Historical stock prices
Current Share Price€3.32
52 Week High€4.92
52 Week Low€2.84
Beta0.86
1 Month Change-0.15%
3 Month Change-7.65%
1 Year Change-8.29%
3 Year Change-17.21%
5 Year Change-84.59%
Change since IPO-74.38%

Recent News & Updates

Genfit S.A.'s (EPA:GNFT) 26% Price Boost Is Out Of Tune With Revenues

Jan 03
Genfit S.A.'s (EPA:GNFT) 26% Price Boost Is Out Of Tune With Revenues

Recent updates

Genfit S.A.'s (EPA:GNFT) 26% Price Boost Is Out Of Tune With Revenues

Jan 03
Genfit S.A.'s (EPA:GNFT) 26% Price Boost Is Out Of Tune With Revenues

Health Check: How Prudently Does Genfit (EPA:GNFT) Use Debt?

Sep 22
Health Check: How Prudently Does Genfit (EPA:GNFT) Use Debt?

Revenue Downgrade: Here's What Analysts Forecast For Genfit S.A. (EPA:GNFT)

Jul 05
Revenue Downgrade: Here's What Analysts Forecast For Genfit S.A. (EPA:GNFT)

Genfit S.A. (EPA:GNFT) Investors Are Less Pessimistic Than Expected

Jun 23
Genfit S.A. (EPA:GNFT) Investors Are Less Pessimistic Than Expected

We Think Genfit (EPA:GNFT) Can Manage Its Debt With Ease

Dec 28
We Think Genfit (EPA:GNFT) Can Manage Its Debt With Ease

New Forecasts: Here's What Analysts Think The Future Holds For Genfit S.A. (EPA:GNFT)

Sep 30
New Forecasts: Here's What Analysts Think The Future Holds For Genfit S.A. (EPA:GNFT)

Downgrade: Here's How Analysts See Genfit S.A. (EPA:GNFT) Performing In The Near Term

Jun 29
Downgrade: Here's How Analysts See Genfit S.A. (EPA:GNFT) Performing In The Near Term

Genfit's(EPA:GNFT) Share Price Is Down 85% Over The Past Five Years.

Mar 14
Genfit's(EPA:GNFT) Share Price Is Down 85% Over The Past Five Years.

Is Genfit (EPA:GNFT) A Risky Investment?

Nov 28
Is Genfit (EPA:GNFT) A Risky Investment?

Shareholder Returns

GNFTFR BiotechsFR Market
7D2.3%1.0%0.4%
1Y-8.3%-1.8%9.6%

Return vs Industry: GNFT underperformed the French Biotechs industry which returned -1.8% over the past year.

Return vs Market: GNFT underperformed the French Market which returned 10.6% over the past year.

Price Volatility

Is GNFT's price volatile compared to industry and market?
GNFT volatility
GNFT Average Weekly Movement5.6%
Biotechs Industry Average Movement5.8%
Market Average Movement4.2%
10% most volatile stocks in FR Market9.8%
10% least volatile stocks in FR Market2.2%

Stable Share Price: GNFT has not had significant price volatility in the past 3 months.

Volatility Over Time: GNFT's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1999154M. Prigenthttps://www.genfit.com

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia.

Genfit S.A. Fundamentals Summary

How do Genfit's earnings and revenue compare to its market cap?
GNFT fundamental statistics
Market cap€165.04m
Earnings (TTM)-€34.17m
Revenue (TTM)€29.22m

5.6x

P/S Ratio

-4.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GNFT income statement (TTM)
Revenue€29.22m
Cost of Revenue€0
Gross Profit€29.22m
Other Expenses€63.39m
Earnings-€34.17m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

Apr 04, 2024

Earnings per share (EPS)-0.69
Gross Margin100.00%
Net Profit Margin-116.97%
Debt/Equity Ratio93.1%

How did GNFT perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.